Abstract
The metabolic syndrome (MetS) is a constellation of metabolic risk factors reflecting overnutrition and sedentary lifestyle and its increasing prevalence is reaching epidemic proportions. The importance of MetS lies in its close association with the risk of cardiometabolic disease. In this scenario, the principal goals of pharmacological therapy for these patients are to achieve and maintain an optimal cardiometabolic control, including lipids, blood glucose and blood pressure; in order to prevent and treat potential complications. Moreover nutrition has commonly been accepted as a cornerstone of treatment for MetS, with the expectation that an appropriate intake of energy and nutrients will improve its control. However the question arises as to whether dietary therapy may require a more personalised approach. In this regard improvements in genetic analysis have enhanced our understanding of the role of genetics in this dietrelated condition. In this review we will present recent data highlighting the importance of gene-nutrient interactions in the context of MetS risk.
Keywords: Diet, gene-diet interaction, nutrigenomics, metabolic syndrome, polymorphism, diabetes mellitus.
Current Vascular Pharmacology
Title:Nutrigenetics, Metabolic Syndrome Risk and Personalized Nutrition
Volume: 11 Issue: 6
Author(s): Pablo Perez-Martinez, Catherine M. Phillips, Javier Delgado-Lista, Antonio Garcia-Rios, Jose Lopez-Miranda and Francisco Perez-Jimenez
Affiliation:
Keywords: Diet, gene-diet interaction, nutrigenomics, metabolic syndrome, polymorphism, diabetes mellitus.
Abstract: The metabolic syndrome (MetS) is a constellation of metabolic risk factors reflecting overnutrition and sedentary lifestyle and its increasing prevalence is reaching epidemic proportions. The importance of MetS lies in its close association with the risk of cardiometabolic disease. In this scenario, the principal goals of pharmacological therapy for these patients are to achieve and maintain an optimal cardiometabolic control, including lipids, blood glucose and blood pressure; in order to prevent and treat potential complications. Moreover nutrition has commonly been accepted as a cornerstone of treatment for MetS, with the expectation that an appropriate intake of energy and nutrients will improve its control. However the question arises as to whether dietary therapy may require a more personalised approach. In this regard improvements in genetic analysis have enhanced our understanding of the role of genetics in this dietrelated condition. In this review we will present recent data highlighting the importance of gene-nutrient interactions in the context of MetS risk.
Export Options
About this article
Cite this article as:
Perez-Martinez Pablo, Phillips M. Catherine, Delgado-Lista Javier, Garcia-Rios Antonio, Lopez-Miranda Jose and Perez-Jimenez Francisco, Nutrigenetics, Metabolic Syndrome Risk and Personalized Nutrition, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128120911
DOI https://dx.doi.org/10.2174/157016111106140128120911 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias
Current Pharmaceutical Design Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Prevalence, Incidence, Risk and Protective Factors of Amnestic Mild Cognitive Impairment in the Elderly in Shanghai
Current Alzheimer Research Steerable Sheath Technology in the Ablation of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Antibacterial and Antioxidant Property of Streptomyces cinnamonensis VITNS1 Isolated from Serkadu Region, Vellore, Tamil Nadu, India
Anti-Infective Agents The Anti Inflammatory Effects of High Density Lipoproteins
Current Medicinal Chemistry Is Fast Food Addictive?
Current Drug Abuse Reviews An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets Coronary Microcirculation and Ischemic Heart Disease, Today
Current Pharmaceutical Design Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Caregiver Burden in Fragile X Families
Current Psychiatry Reviews Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective
Current Topics in Medicinal Chemistry Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Treatment of Fabry Disease: Current and Emerging Strategies
Current Pharmaceutical Biotechnology Fluoroquinolones: Blessings Or Curses
Current Drug Targets Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets